Volume | 40,000 |
|
|||||
News | - | ||||||
Day High | 0.0005 | Low High |
|||||
Day Low | 0.0005 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Q BioMed Inc (CE) | QBIO | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.0005 | 0.0005 | 0.0005 | 0.0005 | 0.0005 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1 | 40,000 | $ 0.0005 | $ 20 | - | 0.000001 - 0.0155 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:34:13 | 40,000 | $ 0.0005 | USD |
Q BioMed Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
0 | 145.09M | 41.00M | 284k | -3.49M | -0.02 | 0.00 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Q BioMed (CE) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QBIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.000001 | 0.0005 | 0.000001 | 0.0005 | 20,650 | 0.0005 | 49,900.00% |
1 Month | 0.0001 | 0.0005 | 0.000001 | 0.0004041 | 5,305 | 0.0004 | 400.00% |
3 Months | 0.000001 | 0.0005 | 0.000001 | 0.0001103 | 62,588 | 0.0005 | 49,900.00% |
6 Months | 0.001 | 0.0012 | 0.000001 | 0.0004684 | 114,359 | -0.0005 | -50.00% |
1 Year | 0.0113 | 0.0155 | 0.000001 | 0.0052678 | 112,561 | -0.0108 | -95.58% |
3 Years | 0.93 | 1.06 | 0.000001 | 0.0456873 | 574,171 | -0.9295 | -99.95% |
5 Years | 1.675 | 3.75 | 0.000001 | 0.2270855 | 373,788 | -1.67 | -99.97% |
Q BioMed (CE) Description
Q BioMed Inc. ''Q`` is a biomedical acceleration and development company focused on acquiring companies and biomedical assets in clinical stage or and near revenue development. Q is dedicated to providing these target companies strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need. |